Barclays
NBSE

Barclays’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Barclays’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Hold
0
– – – 7369
2018
Q1 		– Hold
0
– – – 7411
2014
Q4 		– Sell
-4
Closed -$11K – 7675
2014
Q3 		$11K Hold
4
– – ﹤0.01% 6841
2014
Q2 		$15K Buy
+4
New +$15.1K ﹤0.01% 6638

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Barclays's NBSE Position: Q2 2018 in Review

Barclays held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7369.

Barclays first reported a position in NBSE in Q2 2014 and has held it in 2 quarters since. The position peaked at $15K in Q2 2014. 33 funds tracked by Wall St. Rank hold NBSE as of Q2 2018.

  • Barclays held 0 shares of NeuBase Therapeutics, Inc. Common Stock worth $0 as of Q2 2018.
  • Barclays left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q2 2018.
  • NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of Barclays's portfolio in Q2 2018, its #7369 holding.
  • Barclays first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 2 quarters since.
  • Barclays's NeuBase Therapeutics, Inc. Common Stock position peaked at $15K in Q2 2014.
  • 33 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.